<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872090</url>
  </required_header>
  <id_info>
    <org_study_id>P/2015/255</org_study_id>
    <nct_id>NCT02872090</nct_id>
  </id_info>
  <brief_title>Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>LAB-Card</acronym>
  <official_title>Effects of Long Acting Bronchodilators on CARDiac Autonomic Nervous System Control in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this interventional, randomized, double-blind, monocentric, cross-over study is to&#xD;
      quantify the possible deleterious effect on the cardiac autonomic nervous system control of&#xD;
      two long-acting anticholinergic bronchodilatators (tiotropium and glycopyrronium) and one&#xD;
      beta-2 agonist long-acting bronchodilatator (indacaterol ) in patients with mild COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-over study with randomization in terms of 4 treatments: two long-acting&#xD;
      muscarinic antagonists (tiotropium and glycopyrronium), one long-acting beta-adrenoceptor&#xD;
      agonist(indacaterol) and placebo.&#xD;
&#xD;
      Each subject will pass 4 experimental random sessions, separated by at least 48 hours given&#xD;
      the pharmacokinetic properties of the drugs tested. During each of the 4 sessions, blood&#xD;
      pressure will be measured. Drugs inhaled by the patient will be prepared and administered by&#xD;
      the nurse according to the randomization schedule. Patients and investigators will be blinded&#xD;
      regarding the administered drug/placebo (anonymized inhaler). After 15 minutes (at rest, at&#xD;
      neutral temperature), patients will have continuous measurement of blood pressure and heart&#xD;
      rate (by a sphygmomanometer) (1) in supine position and (2) after a passive tilt test on a&#xD;
      tilt test table.&#xD;
&#xD;
      A flow-volume loop (BDV) will be performed after the tilt table test (measurement of Forced&#xD;
      expiratory volume in 1 second (FEV1) and FVC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low-frequency (LF)/High-frequency (HF) ratio in supine position during a tilt table test after bronchodilators inhalation</measure>
    <time_frame>10 minutes</time_frame>
    <description>For each patient, the LF/HF ratio after inhalation of an active drug (indacaterol or glycopyrronium or tiotropium) will be compared to LF / HF ratio measured after inhalation of a placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Slope of baroreflex in supine position</measure>
    <time_frame>10 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LF / HF ratio derived from the spectral analysis of R-R intervals measured after verticalisation during a tilt table test</measure>
    <time_frame>10 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total spectral power during a tilt table tes</measure>
    <time_frame>20 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of HF (gross value then normalized according to the average R-R interval) during a tilt table tes</measure>
    <time_frame>20 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RMSSD (Root Mean Square of the Successive Differences) index during a tilt table test</measure>
    <time_frame>20 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability in blood pressure during a tilt table test</measure>
    <time_frame>20 minutes</time_frame>
    <description>Drugs vs placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive once a week during 4 weeks, in the order: indacaterol, tiotropium, glycopyrronium and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive once a week during 4 weeks, in the order: tiotropium, glycopyrronium, placebo and indacaterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive once a week during 4 weeks, in the order: glycopyrronium, placebo, indacaterol and tiotropium,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients receive once a week during 4 weeks, in the order: placebo, indacaterol and tiotropium and glycopyrronium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <description>inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium</intervention_name>
    <description>inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>photoplethysmography</intervention_name>
    <description>inhalation</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with FEV1 / FVC &lt;70%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  beta blocker&#xD;
&#xD;
          -  supraventricular rhythm disorder&#xD;
&#xD;
          -  previous history of respiratory disease other than COPD&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  autonomic dysfunction&#xD;
&#xD;
          -  dysautonomia&#xD;
&#xD;
          -  renal failure&#xD;
&#xD;
          -  long-term oxygen therapy&#xD;
&#xD;
          -  history of psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu VEIL-PICARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>bronchodilatators</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>cardiovascular system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

